Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) shares were up 4.7% on Monday . The stock traded as high as $735.00 and last traded at $741.02. Approximately 273,511 shares changed hands during trading, a decline of 55% from the average daily volume of 612,186 shares. The stock had previously closed at $707.51.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on REGN shares. Bank of America reaffirmed an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. UBS Group cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $1,130.00 to $738.00 in a research report on Thursday, January 16th. TD Cowen cut their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research report on Tuesday, February 4th. Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a report on Monday, January 27th. Finally, Leerink Partners raised shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $973.13.
Read Our Latest Stock Analysis on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Trading Down 4.0 %
The firm's 50-day moving average is $696.62 and its 200-day moving average is $841.12. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market cap of $75.38 billion, a price-to-earnings ratio of 18.01, a P/E/G ratio of 2.34 and a beta of 0.27.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter last year, the firm posted $11.86 EPS. Regeneron Pharmaceuticals's revenue was up 10.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.
Regeneron Pharmaceuticals Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.51%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.
Hedge Funds Weigh In On Regeneron Pharmaceuticals
Several large investors have recently bought and sold shares of REGN. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 19 shares during the period. Pinney & Scofield Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $25,000. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $26,000. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $28,000. Finally, Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $36,000. 83.31% of the stock is currently owned by institutional investors.
About Regeneron Pharmaceuticals
(
Get Free Report)
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Featured Articles
Before you consider Regeneron Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.
While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
